Introduction
Cryptococcal meningitis (CM) is an opportunistic infection usually seen in immuno-compromised patients, but is also known to affect apparently healthy individuals. It is caused by Cryptococcus neoformans, an ubiquitous encapsulated yeast with a predilection for the central nervous system. Infection occurs via inhalation of C. neoformans spores and it disseminates haematogenously with a predilection for the central nervous system, causing meningitis/meningo-encephalitis. It clinically manifests with sub-acute onset of fever, headache, vomiting with or without focal neurological defi cit and is the AIDS defi ning illnesses in up to 69% of patients with HIV infection. [1] If marrow) including fungal culture, India ink preparation, and cryptococcal antigen test were gathered. All patients were initiated on a standard protocol of amphotericin B with regular monitoring of serum creatinine and potassium levels. Flucytosine was not used. High dose of fl uconazole was used as an alternative if there was a contraindication to amphotericin B. The patients of CM were classifi ed into two groups based on HIV co-infection. All the clinical and laboratory variables were analysed to compare the differences between the two groups of patients.
Laboratory tests
India ink and Gram staining were done on the CSF samples. All the samples of CSF were processed for fungal culture on Sabouraud's dextrose agar, which was incubated at 37°C and 25°C in a biological oxygen demand (BOD) incubator and processed according to a standardised protocol, which was based on the presence of any visible growth. The fungal cultures were followed for 2 weeks. The colonies of C. neoformans were identifi ed, based on their yeast like colony morphology, the presence of spherical yeast cells without hyphae/psesudohyphae on microscopy and a positive urease test.
Statistical methods
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software for Windows version 16.0. Descriptive data are given as mean (SD) or as median (range). Chi-square test or Fisher's exact test was used to compare dichotomous variables and t-test or Mann-Whitney test was used for continuous variables as appropriate. The association of clinical and laboratory features to the outcome were analysed by univariate analysis and their 95% confi dence intervals were calculated. For all the tests, a 2-sided P value of 0.05 or less was considered statistically signifi cant.
This study was approved by the Institutional Review Board of Christian Medical College, Vellore and patient confi dentiality was maintained using unique identifi ers.
Results

Clinical characteristics
During the study period, 117 cases of microbiologically confi rmed CM were admitted in various medical units [ Table 1 ]. Total of 102 (87.2%) cases occurred among HIV infected individual, while 15 (12.8%) occurred among HIV-uninfected patients. CM occurred more commonly among males in both the groups (82.4% and 66.7% respectively, P value = 0.17). The mean age group of the patients with CM and HIV co-infection was 38.2 ± 8.5 years, which was lower as compared to HIV-uninfected patients (45 ± 11.5 years; P value = 0.07). The median duration of symptoms prior to presentation was signifi cantly shorter among the HIV-infected group (20 ± 32 days vs. 30 ± 42 days; P = 0.03).
The most common symptom was headache (94%), followed by vomiting (85%). Fever and alteration of mentation was present in 75% and 41%, respectively. Neck stiffness was present in 84% of the patients. It is interesting to note that 21% of the CM among HIV-infected patients had seizures while HIV-uninfected patients had no seizures (P value = 0.1). All the other symptoms were not signifi cantly different among the HIV-infected and HIV-uninfected patients.
Among HIV-infected patients, CM was the presenting HIV-AIDS defi ning illness in 48/102 (47.1%) of patients. Only 14/102 HIV-infected patients were on anti-retroviral therapy at the time of admission and 6 of them developed CM as an Immune Reactivation Infl ammatory Syndrome (IRIS). No obvious risk factor for CM was identifi able in 6/15 patients, who were HIV uninfected but diabetes mellitus was seen in 4/15 patients. The median peripheral CD 4 T-cell count was signifi cantly higher in the HIV-uninfected group 428 cells/μL (254.5-542.2) as compared with HIV-infected group 42 cells/μL (26.7-70.5). Case fatality rate in the HIV-infected group was 30.6%, while there were no deaths in the HIV-uninfected group.
CSF analysis
Total CSF WBC count was elevated (>5 cells/cu mm) in all the HIV-uninfected patients and in 80.6% of HIV-infected patients. It ranged from 6-620/cu mm with a median of 52 (20-120) in the HIV-uninfected group, whereas the HIV-infected group had a wider range of 1-3500/cu mm with a median of 40 . There was a clear lymphocyte predominance in the CSF with 92.1% and 88.2% in the HIV-infected and HIV-uninfected groups, respectively. Comparison of both the groups showed no statistically signifi cant difference between the CSF lymphocyte counts, CSF protein counts and CSF sugar levels [ Table 2 ].
CSF fungal culture was positive in 112 (95.7%) patients among which 98.2% (110/112) were C. neoformans var. neoformans and 1.8% (2/112) were C. neoformans var. gattii. Both the C. neoformans var. gatti were seen in the immunosuppressed patients. The diagnostic yield of C.neoformans was similar with CSF India ink preparation (89% vs. 87%), CSF fungal culture (95% vs. 87%), and blood culture (100% vs. 75%) in both the groups [ Table 3 ]. Cryptococcus was isolated from the bone marrow cultures of 3 patients.
Since 2005, the hospital admissions of newly diagnosed cases of CM have shown a declining trend among HIV co-infected individuals (P value < 0.01) as shown in Figure 1 .
Discussion
In the decade of the 1950's cryptococcal infection was reported in less than 500 patients globally. [1] With the advent of the AIDS pandemic, there was an increase in the number of cases. However with the successful introduction and widespread accessibility of highly active retroviral therapy under National AIDS control program (NACP), there is a sharp decline in the incidence of new cases of invasive cryptococcal diseases. [2, 4] Other high risk groups for CM are transplant recipients on immunosuppressants and those with haematopoietic malignancies, chronic renal failure, solid organ malignancy and liver cirrhosis. Cryptococcosis has been reported from many parts of India in those with underlying risk factors and in apparently healthy individuals as well.
In our study, 88.7% (102/117) of the patients with CM had HIV infection, which is comparable to the rate (79.4%) reported in other recent studies. [1] However, a study done in South India between 1978 and 1995 showed that a much a smaller proportion of patients with CM (43.9%) were associated with HIV infection. [5] This refl ects the impact of the HIV pandemic in India and supports the fact that there has been a parallel increase in the incidence of HIV and cryptococcal infections. In contrast, data from the developed countries show a higher percentage of HIV uninfected patients with CM. [1] This may be explained by a higher number of post-transplant patients and the higher use of immunosuppressant drugs.
In our hospital, out of a total of 2067 HIV related admissions from 2005-2013, 117 (5.6%) were due to CM. Lakshmi et al., reported a much lesser prevalence of 2.09% in their HIV reactive cohort in 2007. [6] Males are more commonly infected than females, which may refl ect a higher prevalence of HIV infection among males and a higher exposure to cryptococcus rather than a difference in host susceptibility. CM was the AIDS defi ning illness in 47.1% of our patients, a rate much lesser than 78.5% reported in a study done in South India before 1995. [5] This is probably related to early diagnosis of HIV infection and widespread use of National AIDS Control Organization (NACO)-free ART.
Clinical presentation and the course of CM are usually indolent with symptoms starting over 1-3 weeks. Usual symptoms are headache and altered mental status, including personality changes, confusion, lethargy, obtundation, and coma. In our study, headache was the most common presenting complaint followed by nausea and [8, 9] Contrary to our fi ndings, other studies had shown that HIV-infected patients had lesser CSF pleocytosis, lower CSF protein response and a higher rate of isolation from non-neural sites. One of our patients had a CSF WBC count of 3500 cells/cu mm, probably the highest reported value for CM.
According to previous studies on HIV-infected patients with CM, a low CD 4 T-cell count <20/μL and low CSF WBC count have been found to be associated with poor prognosis where as an initial high cryptococcal antigen titre and hydrocephalus were related to poor outcomes among HIV-uninfected patients. In our study, the overall case fatality rate was 26.3% with all the deaths being in the HIV-infected group. This is in contrast to studies on CM from the developed countries where HIV-uninfected patients have a higher mortality than HIV-infected patients (13.3% vs. 10.5%; P, 0.0001). [1] Within India, the reported mortality rates due to CM have varied considerably from 18-38.3%. [5, 7] Overall, there is a trend showing a decline in incidence of CM and increasingly successful treatment of this infection from 38.33% recovery before 1995 to 73.7% recovery in our study patients [ Table  4 ]. Early diagnosis of HIV infection and appropriate initiation of anti-retroviral therapy to maintain a higher CD 4 T-cell count may be the most important step to decrease the incidence of cryptococcal infection. Even in HIV-uninfected patients a high index of clinical suspicion and mycological surveillance is needed, as majority of patients respond well to therapy if treated early.
Conclusion
In India, HIV infection continues to be an important risk factor for CM and is an important contributor to morbidity and mortality. HIV-infected patients with CM have a worse outcome compared to HIV-uninfected patients. The overall trend over 3 decades shows increasingly successful rates of treatment and hence early diagnosis and treatment are of paramount importance. 
